Edition:
United States

Abiomed Inc (ABMD.O)

ABMD.O on Nasdaq

157.42USD
20 Sep 2017
Change (% chg)

$0.32 (+0.20%)
Prev Close
$157.10
Open
$157.32
Day's High
$157.92
Day's Low
$156.53
Volume
191,715
Avg. Vol
308,599
52-wk High
$159.80
52-wk Low
$95.14

Chart for

About

ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops,... (more)

Overall

Beta: 0.25
Market Cap(Mil.): $6,928.45
Shares Outstanding(Mil.): 44.10
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.13 16.25
EPS (TTM): -- -- --
ROI: -- 9.49 14.87
ROE: -- 14.72 13.89

BRIEF-Abiomed receives FDA PMA approval for Impella RP for right heart failure

* Abiomed receives FDA PMA approval for Impella RP for right heart failure Source text for Eikon: Further company coverage:

Sep 20 2017

BRIEF-Abiomed maintains fiscal year 2018 revenue guidance

* Says ‍is maintaining its fiscal year 2018 revenue guidance of $560 million to $575 million - SEC filing​

Aug 28 2017

BRIEF-ABIOMED says CFO Michael Tomsicek resigns

* ABIOMED announces resignation of chief financial officer and welcomes back former chief financial officer as consultant

Aug 28 2017

BRIEF-Abiomed Q1 gaap earnings per share $0.82

* Abiomed announces Q1 FY 2018 revenue of $132.5 million, up 29% over prior year

Jul 27 2017

BRIEF-Abiomed reports Q1 EPS $0.82

* Abiomed announces Q1 FY 2018 revenue of $132.5 million, up 29 pct over prior year

Jul 27 2017

BRIEF-New study with Abiomed's Impella 2.5 Heart Pump demonstrates potential survival with pre-PCI insertion in heart attacks with the left main coronary artery

* New study with Abiomed's Impella 2.5® heart pump demonstrates potential survival with pre-PCI insertion in heart attacks with the left main coronary artery Source text for Eikon: Further company coverage:

Jun 30 2017

BRIEF-Abiomed says enrolled first patient in FDA approved prospective feasibility study

* Abiomed - enrollment of first patient in fda approved prospective feasibility study, STEMI door to unloading with Impella CP system in acute myocardial infarction

May 04 2017

BRIEF-Abiomed Q4 gaap earnings per share $0.33

* Abiomed announces Q4 fy 2017 revenue of $124.7 million, up 33% over prior year and total year revenue of $445.3 million, up 35% over prior year

May 04 2017

BRIEF-Abiomed announces Q4 revenue of $124.7 million, up 33 pct

* Abiomed announces q4 fy 2017 revenue of $124.7 million, up 33% over prior year and total year revenue of $445.3 million, up 35% over prior year

May 04 2017

Earnings vs. Estimates